Cover Image
市場調查報告書

原發性免疫缺陷症市場 (各疾病:抗體不全,細胞免疫力缺乏、先天性免疫疾病、各檢查、各治療、各地區) -全球產業分析、規模、佔有率、成長、趨勢,及2015∼2023年的預測

Primary Immunodeficiency Diseases Market (By Disease: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder; By Test; By Treatment; By Geography) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

出版商 Transparency Market Research 商品編碼 347757
出版日期 內容資訊 英文 117 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
原發性免疫缺陷症市場 (各疾病:抗體不全,細胞免疫力缺乏、先天性免疫疾病、各檢查、各治療、各地區) -全球產業分析、規模、佔有率、成長、趨勢,及2015∼2023年的預測 Primary Immunodeficiency Diseases Market (By Disease: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder; By Test; By Treatment; By Geography) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
出版日期: 2015年11月24日 內容資訊: 英文 117 Pages
簡介

本報告提供原發性免疫缺陷症市場相關調查、市場趨勢與今後的預測、市場機會等,加上各疾病/各檢查/各治療/各地區趨勢,及進入的主要企業的簡介等彙整。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場趨勢
  • 促進要素
    • 政府對原發性免疫缺陷症的新治療方法的認證
    • 全球原發性免疫缺陷症發病率上升
    • 意識提高促進對原發性免疫缺陷症治療的需求
  • 阻礙要素
    • 恰當償付的不足和治療費高阻礙市場成長
    • 未診斷的患者數增加影響收益的流程
  • 機會
    • 新興市場上新生兒篩檢市場機會
  • 波特五力分析
  • 市場魅力度分析
  • 競爭環境
  • 開發平台分析 (第一階段、第二階段) 免疫球蛋白
  • 開發平台分析 (第三階段) 免疫球蛋白

第4章 各疾病市場

  • 簡介
  • 抗體不全
  • 細胞免疫力缺乏
  • 先天性免疫疾病

第5章 各檢查

  • 簡介
  • 血液檢驗
  • 產前檢查

第6章 各治療市場

  • 簡介
  • 免疫球蛋白置換法
  • 抗生素治療
  • 幹細胞治療
  • 其他治療方法

第7章 各地區市場

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第8章 建議

第9章 企業簡介

  • Baxter International, Inc.
  • Biotest AG
  • CSL Behring LLC
  • Bio Products Laboratory Ltd.
  • Kedrion S.p.A.
  • LFB S.A.
  • Octapharma AG
  • Grifols S.A.
目錄

This report on the primary immunodeficiency diseases (PIDD) market studies the current as well as future prospects of the market. The stakeholders of this report include pharmaceuticals companies, diagnostic kits providers, distributors, care providers and insurance companies (payers) and other intermediaries engaged in PIDD as well as new entrants that are planning to enter in this segment. This report comprises an elaborate executive summary with a market snapshot providing overall information of various segments and sub-segments considered in the study scope. The executive summary also provides overall information and data analysis of the PIDD market with respect to the leading market segments based on Disease, Test, Treatment and Geography. The market revenue in terms of USD million for the period between 2013 and 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 are provided for all segments and sub-segments considered under the scope of study, considering 2014 as the base year. Pipeline analysis (qualitative) for Phase I, II candidates whereas a detailed quantitative aspect (US$ Mn) for III drugs are illustrated in the market overview chapter.

The report analyzed the PIDD market from four prominent segments: by Disease, by Test, by Treatment and by Geography. In terms of market by disease the overall market is segmented into three broad categories: Antibody Deficiency, Cellular Immunodeficiency and Innate Immune Disorder. The antibody deficiency market is further analyzed and estimated for Agammaglobulinaemia, Common Variable Immune Deficiency, Selective IgA Deficiency, IgG Subclass Deficiency and Others. Whereas, cellular immunodeficiency market is sub-segmented into Ataxia Telangiectasia, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome, DiGeorge Syndrome and Others. The innate immune disorder market include Complement Deficiencies, Hyper IgE Syndrome and Others. Moreover this report also studies the global market by test for diagnosis which encompasses blood test and prenatal testing. The global PIDD market by treatment include both qualitative and quantitative analysis for immunoglobulin replacement therapy, antibiotics therapy, stem cell and gene therapy and others.

Geographically the market is divided into four major regions: North America, Europe, Asia Pacific and Rest of the World. The North America market incorporates The United States and Canada. The Europe region is accessed for Germany, United Kingdom and Rest of Europe. The Asia Pacific (APAC) market is sub-segmented into India, China and Rest of APAC. Rest of the World (RoW) include Latin America, Middle East and North Africa and Rest of RoW

Each of the aforementioned segments has been analyzed in detail for market trends, recent developments, outlook, and opportunities. The market overview section of the report explores market dynamics such as drivers, restraints, and opportunities that currently have strong impact on the global PIDD market which could influence the market in the future as well. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition between leading market players in the U.S. market. Porter's five forces analysis is also explained in this section to understand the market in U.S. considering different parameters that have an impact on the sustainability of the companies operating in the market.

The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their respective market shares across the globe. The recommendations section included in the report would assist existing market players in targeting the end users and stakeholders of PIDD and also to those aiming to seek an entry. The report also profiles major players in the PIDD market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Some of the leading companies operating in primary immunodeficiency diseases market across the globe. These encompasses Baxter International, Inc., Biotest AG, CSL Behring LLC, Bio Products Laboratory Ltd., Kedrion S.p.A., LFB S.A., Octapharma AG and Grifols S.A.

The global primary immunodeficiency diseases market is segmented into the following categories:

Global Primary Immunodeficiency Diseases Market, by Disease

  • Antibody Deficiency
    • Agammaglobulinaemia ((X-Linked and Autosomal Recessive)
    • Common Variable Immune Deficiency
    • Selective IgA Deficiency
    • IgG Subclass Deficiency
    • Others
  • Cellular Immunodeficiency
    • Ataxia Telangiectasia
    • Hyper IgM Syndromes
    • Wiskott-Aldrich Syndrome
    • DiGeorge Syndrome
    • Others
  • Innate Immune Disorders
    • Complement Deficiencies
    • Hyper IgE Syndrome
    • Others

Global Primary Immunodeficiency Diseases Market, by Test

  • Blood Test
  • Prenatal Testing

Global Primary Immunodeficiency Diseases Market, by Treatment

  • Immunoglobulin Replacement Therapy
  • Antibiotic Therapy
  • Stem cell and Gene Therapy
  • Others

Global Primary Immunodeficiency Diseases Market, by Geography

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Rest of the World

Table of Contents

1. Introduction

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Market Segmentation

2. Executive Summary

  • 2.1. Market Snapshot: Global Primary Immunodeficiency Diseases Market, 2014 and 2023E
  • 2.2. Global Primary Immunodeficiency Diseases Market Revenue, by Disease, 2014 (US$ Mn)
  • 2.3. Global Primary Immunodeficiency Diseases Market Revenue, by Subclass Disease, 2014 (US$ Mn)
  • 2.4. Global Primary Immunodeficiency Diseases Market Revenue, by Test, 2014 (US$ Mn)
  • 2.5. Global Primary Immunodeficiency Diseases Market Revenue, by Treatment, 2014 (US$ Mn)
  • 2.6. Comparative Analysis: Global Primary Immunodeficiency Diseases Market, by Geography 2014 & 2023 (Value %)

3. Market Overview

  • 3.1. Market Dynamics
  • 3.2. Drivers
    • 3.2.1. Government approval of new therapies for the PIDD treatment
    • 3.2.2. Gradual increase in the incidence of primary immunodeficiency diseases globally
    • 3.2.3. Rising awareness campaigns drive demand for PIDD therapeutics or therapy
  • 3.3. Restraints
    • 3.3.1. Lack of Adequate Reimbursement and High Treatment Cost Hindering PIDD Market Growth
    • 3.3.2. Rising Number of Undiagnosed Patients Affecting Revenue Inflow
  • 3.4. Opportunities
    • 3.4.1. New Born Screening in Emerging Markets Expected to Provide New Opportunities
  • 3.5. Porter's Five Forces Analysis, Global Primary Immunodeficiency Diseases Market
  • 3.6. Market Attractiveness Analysis, by Geography
  • 3.7. Competitive Landscape (Market Share Analysis), by Key Players
  • 3.8. Pipeline Analysis (Phase I and Phase II): Immunoglobulins
  • 3.9. Pipeline Analysis: (Phase III): Immunoglobulins (US$ Mn)

4. Primary Immunodeficiency Diseases Market, by Disease

  • 4.1. Introduction
  • 4.2. Antibody Deficiency
    • 4.2.1. Global Agammaglobulinaemia Market Revenue, 2013-2023, (US$ Mn)
    • 4.2.2. Global Common Variable Immune Deficiency Market Revenue, 2013-2023, (US$ Mn)
    • 4.2.3. Global Selective IgA Deficiency (SIgAD) Market Revenue, 2013-2023, (US$ Mn)
    • 4.2.4. Global IgG Subclass Deficiency Market Revenue, 2013-2023, (US$ Mn)
    • 4.2.5. Global Other Antibody Deficiency Market Revenue, 2013-2023, (US$ Mn)
  • 4.3. Cellular Immunodeficiency
    • 4.3.1. Global Ataxia Telangiectasia Market Revenue, 2013-2023, (US$ Mn)
    • 4.3.2. Global Hyper IgM Syndromes Market Revenue, 2013-2023, (US$ Mn)
    • 4.3.3. Global Wiskott-Aldrich Syndrome Market Revenue, 2013-2023, (US$ Mn)
    • 4.3.4. Global DiGeorge Syndrome Market Revenue, 2013-2023, (US$ Mn)
    • 4.3.5. Global Other Cellular Immunodeficiency Market Revenue, 2013-2023, (US$ Mn)
  • 4.4. Innate Immune Disorder
    • 4.4.1. Global Complement Deficiencies Market Revenue, 2013-2023, (US$ Mn)
    • 4.4.2. Global Hyper IgE Syndrome Market Revenue, 2013-2023, (US$ Mn)
    • 4.4.3. Global Other Innate Immune Disorder Market Revenue, 2013-2023, (US$ Mn)

5. Primary Immunodeficiency Diseases Market, by Test

  • 5.1. Introduction
  • 5.2. Global Primary Immunodeficiency Diseases Market Revenue, by Blood Test, 2013-2023 (US$ Mn)
  • 5.3. Global Primary Immunodeficiency Diseases Market Revenue, by Prenatal Testing, 2013-2023 (US$ Mn)

6. Primary Immunodeficiency Diseases Market, by Treatment

  • 6.1. Introduction
  • 6.2. Global Immunoglobulin Replacement Therapy Market Revenue, 2013-2023 (US$ Mn)
  • 6.3. Global Antibiotics Therapy Market Revenue, 2013-2023, (US$ Mn)
  • 6.4. Global Stem cell and Gene Therapy Market Revenue, 2013-2023, (US$ Mn)
  • 6.5. Global Other Primary Immunodeficiency Disease Treatments Market Revenue, 2013-2023, (US$ Mn)

7. Primary Immunodeficiency Diseases Market, by Geography

  • 7.1. Introduction
  • 7.2. North America Primary Immunodeficiency Diseases Market Revenue, by Country, 2013-2023 (US$ Mn)
  • 7.3. Europe Primary Immunodeficiency Diseases Market, by Country, 2013-2023 (US$ Mn)
  • 7.4. Asia Pacific Primary Immunodeficiency Diseases Market Revenue, by Country, 2013-2023 (US$ Mn)
  • 7.5. Rest of the World Primary Immunodeficiency Diseases Market Revenue, by Country, 2013-2023 (US$ Mn)

8. Recommendations

9. Company Profiles

  • 9.1. Baxter International, Inc.
  • 9.2. Biotest AG
  • 9.3. CSL Behring LLC
  • 9.4. Bio Products Laboratory Ltd.
  • 9.5. Kedrion S.p.A.
  • 9.6. LFB S.A.
  • 9.7. Octapharma AG
  • 9.8. Grifols S.A.
Back to Top